Sponging of mirna-146a using aav-anti-mirna-146a-vectors mediates synaptic and amyloidogenic neuropathology and cognitive deficits in a 5xfad murine model of alzheimer’s disease

Yuhai Zhao,Peter N. Alexandrov,Prerna Dua,Surjyadipta Bhattacharjee,Christian Clement,Frank Culicchia,James M. Hill,Walter J. Lukiw

DOI: https://doi.org/10.1016/j.jalz.2016.06.1301

2016-01-01

Alzheimer s & Dementia

Abstract:Human and murine brains retain discrete populations of micro RNA (miRNA) species that support homeostatic brain gene expression functions, and specific miRNA abundances are significantly and progressively altered in neurological disorders such as Alzheimer disease (AD), prion disease (PrD) and transgenic AD (Tg-AD) murine models when compared to age-matched controls. The innate-immune and pro-inflammatory, NF-kB-regulated 22-nucleotide single-stranded miRNA-146a is significantly up-regulated in parallel with the development of AD and PrD and with the onset of amyloidogenesis in several Tg-AD murine models. Here for the first time we provide evidence of significant up-regulation of miRNA-146a in amyloid-and-cytokine-stressed human neuronal-glial cells in primary co-culture and in the brains of 5xFAD mice [Tg(APPSwFlLon,PSEN1*M146L *L286V)6799Vas] which bear 5 (APP695+PSEN1) mutations that strongly drive the generation of Aβ42 peptides. AAV-miRNA vectors, microRNA analysis, 5xFAD Tg-AD models, RNA sequencing, RT-PCR, LED-Northern, microfluidic and bioinformatics technologies. Using stereotactic bilateral hippocampal injection of a scrambled AAV-miRNA-146a vector into 5xFAD brains as a baseline, selective AAV-miRNA-146a sponging vectors delivered into the hippocampus of 5xFAD mice exhibited (i) decreases in host miRNA-146a expression; (ii) increases in expression of the complement control glycoprotein complement factor H (CFH); (iii) decreases in BACE1, sAPPβsw and the generation of Aβ42 peptides; (iv) decreases in the expression of inflammatory and microglial markers including cyclooxygenase-2 (COX-2), glial fibrillary acidic protein (GFAP) and Iba1; (v) increased expression of the synaptic markers SYN1 and NR2B; and (vi) a significant improvement in cognitive performance in maze tests (NOR and Y-maze). Collectively, the results suggest that the implementation of a novel therapeutic strategy involving the sponging of miRNA-146a and related pro-inflammatory, pathogenic miRNAs may be useful in the effective treatment of AD and other progressive, age-related neurological disorders. Support: Research on miRNA in the Lukiw laboratory involving the innate-immune response in AD, AMD and in other forms of neurological or retinal disease, amyloidogenesis and neuro-inflammation was supported through an unrestricted grant to the LSU Eye Center from Research to Prevent Blindness (RPB); the Louisiana Biotechnology Research Network (LBRN) and grants from the NIH NEI and NIA.